KangFuXin Liquid in the Treatment of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis

Table 2

Study

Sample

Age

Duration of treatment (years)

Diagnostic criteria

Wagner

Baseline data comparable

Incomplete outcome data

Selective reporting

ADs

E

C

E

C

E

C

Ma [21]

21

21

52.4 ± 4.2

51.3 ± 4.0

11.4 ± 3.6

WHO

Yes

Yes

No

No

NR

Huang [29]

50

50

NR

NR

NR

NR

Yes

Yes

No

No

NR

Wang and Qu [23]

50

56

57.9 ± 8.9

58.7 ± 7.7

NR

NR

No

Yes

No

No

NR

Huang [15]

67

67

54

56

NR

WHO1995

Yes

Yes

No

No

NR

Gong[30]

60

60

69.8

>2

CMA1995

No

Yes

No

No

NR

Qi [22]

51

50

65.1 ± 5.7

7.9 ± 3.1

IUA2013

No

Yes

No

No

Yes (4 patients in the experimental group and 5 patients in the control group reported headache, dizziness, palpitations, and dysfunction of liver and kidney)

Feng and Zhao [28]

28

28

34–70

38–69

NR

Guidelines of type 2 diabetes in China 2007

No

Yes

No

No

NR

Shi [25]

24

18

59.5 ± 9.8

66.5 ± 8.1

1.8 ± 0.5

1.7 ± 0.5

ADA

Yes

Yes

No

No

NR

Sun and Gong [26]

38

30

60.2 ± 5.5

11.4 ± 3.6

WHO 2007

Yes

Yes

No

No

NR

Yu [27]

10

10

40–65

10.6 ± 4.4

11.1 ± 4.2

WHO 1999

Yes

Yes

No

No

NR

Zou and Liu [24]

50

50

50.40 ± 1.92

50.14 ± 1.53

10.87 ± 3.64

11.37 ± 3.58

NR

No

Yes

No

No

NR

E, experimental group; C, control group; ADs, adverse events; NR, no report; ADA, American Diabetes Association; WHO, World Health Organization; IUA, International Union of Angiology; CMA, Chinese medical association.